Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Operations (2023 - 2025)

Historic Cash from Operations for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.1 million.

  • BioLineRx's Cash from Operations rose 7856.49% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year increase of 5545.72%. This contributed to the annual value of -$43.9 million for FY2024, which is 9405.96% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Cash from Operations is -$2.1 million, which was up 7856.49% from -$177000.0 recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Cash from Operations registered a high of $5.0 million during Q4 2023, and its lowest value of -$14.1 million during Q1 2024.
  • For the 3-year period, BioLineRx's Cash from Operations averaged around -$6.5 million, with its median value being -$8.6 million (2024).
  • As far as peak fluctuations go, BioLineRx's Cash from Operations plummeted by 27251.05% in 2024, and later skyrocketed by 9843.76% in 2025.
  • BioLineRx's Cash from Operations (Quarter) stood at $5.0 million in 2023, then crashed by 272.51% to -$8.6 million in 2024, then skyrocketed by 75.54% to -$2.1 million in 2025.
  • Its Cash from Operations was -$2.1 million in Q3 2025, compared to -$177000.0 in Q2 2025 and -$2.6 million in Q1 2025.